The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)-Reference-Cited by-同舟云学术

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)

Published:2011-06 Issue:6 Volume:35 Page:777-782
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Deau Bénédicte,Nicolini Franck E.,Guilhot Joelle,Huguet Françoise,Guerci Agnès,Legros Laurence,Pautas Cécile,Berthou Christian,Guyotat Denis,Cony-Makhoul Pascale,Gardembas Martine,Michallet Mauricette,Hayette Sandrine,Cayuela Jean Michel,Weiss Isabelle Radford,Réa Delphine,Castaigne Sylvie,Mahon François-Xavier,Guilhot François,Rousselot Philippe

Funder

Ministry of Health Programme National Hospitalier de Recherche Clinique

CHU de Poitiers

The French Intergroup for CML (Fi-LMC)

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference20 articles.

1. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia,2009

2. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis;de Lavallade;J Clin Oncol,2008

3. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase;Kantarjian;Cancer,2001